Transient Elastography Market Report 2026

The transient elastography market size has grown rapidly in recent years. It will grow from $1.44 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, limitations of invasive liver biopsy procedures, adoption of ultrasound-based diagnostics, expansion of hepatology services, rising awareness of liver health monitoring.

The transient elastography market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing demand for point-of-care diagnostic devices, rising investments in early disease detection, expansion of screening programs for hepatitis and fibrosis, growing adoption of portable diagnostic tools, increasing integration of ai-assisted image analysis. Major trends in the forecast period include increasing adoption of non-invasive liver diagnostics, rising demand for portable elastography devices, growing integration of elastography with ultrasound platforms, expansion of routine liver disease screening, enhanced focus on early fibrosis detection.

The rising prevalence of chronic liver diseases is expected to drive the growth of the transient elastography market. Chronic liver disease is a long-term, progressive condition in which liver function gradually declines due to ongoing inflammation or scarring. Excessive alcohol consumption is a key contributor to liver fibrosis and cirrhosis, increasing the need for regular liver health assessments. This growing burden of alcohol-related and other chronic liver conditions is fueling demand for transient elastography as a non-invasive tool to measure liver stiffness and detect early signs of deterioration. For example, in April 2024, GOV.UK reported that hospital admission rates due to liver disease continue to rise, with admissions reaching 155.2 (152.9-157.5) per 100,000 population in the financial year ending 2023, up from 150.6 (148.2-152.9) the previous year. Therefore, the increasing prevalence of chronic liver diseases is driving market growth for transient elastography.

Companies in the transient elastography market are focusing on innovative products, such as visual transient elastography, to provide real-time visualization of liver tissue stiffness, improve diagnostic accuracy, and support earlier detection and monitoring of liver diseases through non-invasive imaging. Visual transient elastography combines ultrasound with elastography to visually map and quantify liver tissue stiffness in real time. For instance, in June 2023, Mindray, a China-based medical device developer, launched the Hepatus 6 Diagnostic Ultrasound System. The system integrates transient elastography with real-time 2D diagnostic ultrasound, enabling simultaneous quantification of liver fibrosis and steatosis while providing conventional ultrasound imaging. Designed specifically for liver evaluation, this platform streamlines non-invasive liver disease detection, diagnosis, and monitoring.

In June 2025, Tawazun Health, a UK-based community and holistic healthcare provider, partnered with LiverScan Group to expand access to FibroScan transient elastography services across the U.K. This collaboration aims to improve early detection and management of liver diseases by enhancing service reach and clinical integration. LiverScan Group is a U.K.-based company specializing in liver health assessment and disease identification using transient elastography technology.

Major companies operating in the transient elastography market are Siemens Healthcare GmbH, GE HealthCare Technologies Inc., Mindray Bio‑Medical Electronics Co. Ltd., Tawazun Health Ltd., Echosens SA., CHISON Medical Technologies Co. Ltd., Neusoft Medical Systems Co. Ltd., Hisky Medical, Wuxi Hisky Medical Technologies Co. Ltd., Nexgen Therapeutics, Liver Scan Group Limited, Eieling Technology Limited, SMEDA Medical Co. Ltd., Sandhill Scientific Inc.

North America was the largest region in the transient elastography market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transient elastography market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transient elastography market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the transient elastography market by increasing costs of imported ultrasound transducers, electronic components, sensors, and precision manufacturing equipment used in device production. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported medical imaging hardware, while Asia-Pacific faces higher costs for expanding diagnostic infrastructure. These tariffs are increasing equipment acquisition costs and slowing device replacement cycles. However, they are also encouraging localized manufacturing, regional assembly of diagnostic devices, and innovation in cost-optimized elastography solutions.

The transient elastography market research report is one of a series of new reports that provides transient elastography market statistics, including transient elastography industry global market size, regional shares, competitors with a transient elastography market share, detailed transient elastography market segments, market trends and opportunities, and any further data you may need to thrive in the transient elastography industry. This transient elastography market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Transient elastography is a non-invasive medical device that measures liver stiffness using painless, ultrasound-based technology. It is commonly used by physicians to evaluate liver health and detect conditions such as fibrosis and cirrhosis at an early stage. The device delivers quick and reliable results without requiring a biopsy, supporting improved patient care through regular monitoring of liver disease progression.

The main products of transient elastography include standalone devices and portable devices. Standalone devices are non-invasive instruments that assess liver stiffness and fat content by sending a painless mechanical vibration into the liver and measuring the speed of the resulting shear wave. Applications include liver disease assessment, hepatitis evaluation, fibrosis detection, cirrhosis monitoring, and other related uses. These devices are used by hospitals, diagnostic centers, research institutes, and other end users.

The transient elastography market consists of sales of fibroscan, hepatus 6 diagnostic ultrasound system, aixplorer ultimate, resona 7 ultrasound system, and logiq e10 series. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.